Seek Returns

VRTX vs. VTRS: Vertex Pharmaceuticals vs. Viatris Stock Comparison

How do Vertex Pharmaceuticals (VRTX) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Vertex Pharmaceuticals (VRTX) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but VRTX is classified in Biotechnology while VTRS is classified in Pharmaceuticals.

Company profile comparison for Vertex Pharmaceuticals (VRTX) and Viatris (VTRS)
Profile ItemVRTXVTRS
NameVertex Pharmaceuticals Incorporated Common StockViatris Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization138.71 billion USD22.83 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJuly 24, 1991March 17, 1980
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

VRTX
VTRS
GSPC
Loading price history…
Vertex Pharmaceuticals (VRTX) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Vertex Pharmaceuticals (VRTX) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Vertex Pharmaceuticals (VRTX) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Vertex Pharmaceuticals (VRTX) and Viatris (VTRS)
MetricVRTXVTRS
Total Return (1Y)34.89%108.98%
Total Return (3Y, Annualized)14.44%36.75%
Total Return (5Y, Annualized)23.65%11.59%

Risk Profile

Drawdown History

VRTX
VTRS
GSPC
Loading price history…
Vertex Pharmaceuticals (VRTX) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Vertex Pharmaceuticals (VRTX) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Vertex Pharmaceuticals (VRTX) and Viatris (VTRS)
MetricVRTXVTRS
Volatility (1Y, Annualized)29.73%32.53%
Beta (5Y)0.290.86
Max Drawdown (5Y)-29.07%-45.69%
Avg. Volume (3M)1.25M8.87M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
VRTX and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Vertex Pharmaceuticals (VRTX) and Viatris (VTRS)
MetricVRTXVTRS
Sharpe Ratio (1Y)1.033.22
Sortino Ratio (1Y)1.685.63

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Vertex Pharmaceuticals (VRTX) reports 20.80%, ranking against industry peers normally.

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.80%

Max
109.18%
VRTX
20.80%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max
109.18%
Q3
6.23%
VTRS
-4.21%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Vertex Pharmaceuticals (VRTX) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Vertex Pharmaceuticals (VRTX) reports 30.70%, ranking against industry peers normally.

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.70%

VRTX
30.70%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max
18.05%
Q3
4.78%
Median
0.00%
VTRS
-4.13%
Q1
-4.14%
Min
-17.05%
Loading chart…
Vertex Pharmaceuticals (VRTX) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Vertex Pharmaceuticals (VRTX) at 35.57% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.57%

Max
83.12%
VRTX
35.57%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max
83.12%
Q3
14.77%
VTRS
13.85%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Vertex Pharmaceuticals (VRTX) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Vertex Pharmaceuticals (VRTX) and Viatris (VTRS)
MetricVRTXVTRS
ROE (TTM)20.80%-4.21%
ROA (TTM)10.62%2.91%
Net Margin (TTM)30.70%-4.13%
Operating Margin (TTM)35.57%13.85%
Gross Margin (TTM)54.81%41.13%

Growth

Revenue Growth

Vertex Pharmaceuticals (VRTX) at 8.90% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Vertex Pharmaceuticals (VRTX) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Vertex Pharmaceuticals (VRTX) nor Viatris (VTRS) reports a EPS growth value for this period, so a direct comparison isn't possible.

Loading chart…
Vertex Pharmaceuticals (VRTX) vs. Viatris (VTRS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Vertex Pharmaceuticals (VRTX) and Viatris (VTRS)
MetricVRTXVTRS
Revenue Growth (YoY)8.90%-2.98%
Revenue Growth (3Y CAGR)10.35%-4.20%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)6.12%--

Financial Strength

Current Ratio (MRQ)

Both Vertex Pharmaceuticals (VRTX) at 2.34 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.34

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VRTX
2.34
Min
0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VTRS
1.55
Min
0.10
Loading chart…
Vertex Pharmaceuticals (VRTX) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Vertex Pharmaceuticals (VRTX) at 0.31 carries an industry-typical debt-to-equity mix, while Viatris (VTRS) at 0.99 uses more debt funding than most peers.

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.31

Max
1.42
Q3
0.65
VRTX
0.31
Median
0.15
Q1
0.02
Min
0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max
1.42
VTRS
0.99
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Vertex Pharmaceuticals (VRTX) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Vertex Pharmaceuticals (VRTX) and Viatris (VTRS)
MetricVRTXVTRS
Current Ratio (MRQ)2.341.55
Debt / Equity (MRQ)0.310.99
Net Debt / EBITDA0.032.64

Dividends

Dividend Yield (TTM)

Vertex Pharmaceuticals (VRTX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

VRTX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS
2.53%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Vertex Pharmaceuticals (VRTX) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Vertex Pharmaceuticals (VRTX) pays no dividend (payout 0.00%).

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

VRTX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS
960.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Vertex Pharmaceuticals (VRTX) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Vertex Pharmaceuticals (VRTX) and Viatris (VTRS)
MetricVRTXVTRS
Dividend Yield (TTM)0.00%2.53%
Dividend Payout Ratio (TTM)0.00%960.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Vertex Pharmaceuticals (VRTX) trades at 35.21 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.21

Max
85.34
Q3
43.46
VRTX
35.21
Median
26.69
Q1
13.30
Min
0.07

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
VTRS
--
Loading chart…
Vertex Pharmaceuticals (VRTX) vs. Viatris (VTRS): VTRS does not report P/E ratio, so it has no value marker; VRTX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Vertex Pharmaceuticals (VRTX) at 10.71 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.71

Max
58.18
Q3
25.77
VRTX
10.71
Median
7.30
Q1
3.01
Min
0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
VTRS
1.55
Min
0.01
Loading chart…
Vertex Pharmaceuticals (VRTX) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 looks cheap against book in the lower P/B ratio quartile, while Vertex Pharmaceuticals (VRTX) at 6.63 carries a premium in the upper quartile — a clear price-to-book gap.

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.63

Max
13.53
VRTX
6.63
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
VTRS
1.67
Min
-5.59
Loading chart…
Vertex Pharmaceuticals (VRTX) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Vertex Pharmaceuticals (VRTX) and Viatris (VTRS)
MetricVRTXVTRS
P/E Ratio (TTM)35.21--
P/S Ratio (TTM)10.711.55
P/B Ratio (MRQ)6.631.67
Free Cash Flow Yield (TTM)1.69%13.84%